Related references
Note: Only part of the references are listed.Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
Michael U. Callaghan et al.
BLOOD (2021)
Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis
Bhavya S. Doshi et al.
HAEMOPHILIA (2021)
Emicizumab prophylaxis: Prospective longitudinal real-world follow-up and monitoring
Assaf A. Barg et al.
HAEMOPHILIA (2021)
Emicizumab in tolerized patients with hemophilia A with inhibitors: A single-institution pediatric cohort assessing inhibitor status
Glaivy Batsuli et al.
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2021)
Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
Patrick T. Ebbert et al.
HAEMOPHILIA (2020)
Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline
P. Vincent Jenkins et al.
HAEMOPHILIA (2020)
Real-world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures
Isabella McCary et al.
HAEMOPHILIA (2020)
Emicizumab treatment and monitoring in a paediatric cohort: real-world data
Assaf A. Barg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Neutralizing antidrug antibody to emicizumab in a patient with severe hemophilia A with inhibitors: New case with detailed laboratory evaluation
Colleen Harkins Druzgal et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A
Georg Gelbenegger et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Safety and efficacy of emicizumab and other novel agents in newborns and infants
Glenn F. Pierce et al.
HAEMOPHILIA (2019)
Emicizumab and thrombosis: The story so far
Michael Makris et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2019)
Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort
Assaf A. Barg et al.
PEDIATRIC BLOOD & CANCER (2019)
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
Steven W. Pipe et al.
LANCET HAEMATOLOGY (2019)
Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis
Glaivy Batsuli et al.
HAEMOPHILIA (2019)
A multicentre, open-label study of emicizumab given every 2 or 4 weeks in children with severe haemophilia A without inhibitors
Midori Shima et al.
HAEMOPHILIA (2019)
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
Guy Young et al.
BLOOD (2019)
Immunogenicity of Emicizumab in People with Hemophilia A (PwHA): Results from the HAVEN 1-4 Studies
Ido Paz-Priel et al.
BLOOD (2018)
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
Johannes Oldenburg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
Midori Shima et al.
BLOOD ADVANCES (2017)
A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects
Naoki Uchida et al.
BLOOD (2016)
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
Midori Shima et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Takehisa Kitazawa et al.
NATURE MEDICINE (2012)
Share Paper
